Athos Therapeutics, Inc.

Athos Therapeutics, Inc. has raised $17.8M in total funding. The most recent round was Series B.

Athos Therapeutics, Inc. is headquartered in Torrance, CA.

Athos Therapeutics Inc. is a clinical stage biotechnology company that pioneers the development of artificial intelligence-based Precision Therapeutics for patients with Inflammatory Bowel Disease and other inflammatory diseases.

Patients with Inflammatory Bowel Disease and other autoimmune/chronic inflammatory diseases need better, more precisely targeted treatments.

Athos develops AI-based precision therapeutics by identifying disease-related factors from clinical and molecular patient datasets, then synthesizing small molecules via a computational medicinal chemistry platform.

They combine medicinal chemistry, systems biology, and a machine learning algorithm to integrate human clinical/molecular data with compound synthesis to identify compounds that safely and efficiently target key disease factors.

Its co-founders include one of the founders of Kite Pharma, which was acquired by Gilead for $12 billion.